ZyVersa Therapeutics Inc. (ZVSA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.10 (+0.00%), Market cap $0.00B, 52-week low–high $0.12 ~ $0.78.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a
Financial statements, price targets, institutional (13F) holdings and related news for ZyVersa Therapeutics Inc. are updated in real time on BlackAll Trade.
ZyVersa Therapeutics Inc. trades at $0.10 (+0.00%). Real-time quotes and charts are available on BlackAll Trade.
ZyVersa Therapeutics Inc. has a market cap of about $0.00B.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platform